Two risk factors for hypozincemia in diabetic β-thalassemia patients: Hepatitis C and deferasirox.
<h4>Background and aim</h4>Hypozincemia is a prevalent adverse consequence in diabetes mellitus (DM) and β-Thalassemia patients. We aimed to evaluate the level of serum zinc in β-thalassemia patients with DM and a risk assessment for hypozincemia.<h4>Methods</h4>The study pop...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2024-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0284267&type=printable |
| _version_ | 1797352477307174912 |
|---|---|
| author | Hadi Darvishi-Khezri Hossein Karami Mohammad Naderisorki Mobin Ghazaiean Mehrnoush Kosaryan Amir Mosanejad-Galchali Aily Aliasgharian Hasan Karami |
| author_facet | Hadi Darvishi-Khezri Hossein Karami Mohammad Naderisorki Mobin Ghazaiean Mehrnoush Kosaryan Amir Mosanejad-Galchali Aily Aliasgharian Hasan Karami |
| author_sort | Hadi Darvishi-Khezri |
| collection | DOAJ |
| description | <h4>Background and aim</h4>Hypozincemia is a prevalent adverse consequence in diabetes mellitus (DM) and β-Thalassemia patients. We aimed to evaluate the level of serum zinc in β-thalassemia patients with DM and a risk assessment for hypozincemia.<h4>Methods</h4>The study population included transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT) with overt DM (fasting plasma glucose (FPG) ≥126 mg/dL, and/or 2-h plasma glucose≥200 mg/dL). Serum zinc concentration was measured by the colorimetric method, and the values below 70 μg/dL were defined as hypozincemia. Myocardial and liver T2*-weighted magnetic resonance imaging (MRI T2*, millisecond [ms]) were valued by a free contrast MRI. The demographic, clinical, paraclinical, and laboratory data were also recorded. The data belonged to the period from December 2018 until December 2020.<h4>Results</h4>Of 64 diabetic β-thalassemia patients, 41 cases had zinc data in their medical files (aged 38 ± 9 years, 48.8% female). 78.05% of patients (n = 32) were TDT, and 21.95% were NTDT (n = 9). The mean ± standard deviation of zinc level was 110.2 ± 127.6 μg/dL. The prevalence of hypozincemia was 9.76%, 95% confidence interval [CI] 0.27 to 19.24 (four cases). After controlling age, the odds of hypozincemia for using deferasirox (DFX) was 8.77, 95% CI 0.60 to 127.1. In β-thalassemia patients, the age-adjusted risk of hypozincemia was calculated at 15.85, 95% CI 0.47 to 529.3 for hepatitis C. The adjusted risk of hypozincemia based on age for antacid use was 6.34, 95% CI 0.39 to 102.7.<h4>Conclusion</h4>In light of this study, as well as hepatitis C, using DFX and antacids is associated with a high risk of hypozincemia amid diabetic β-thalassemia cases. However, upward bias should be taken into consideration. |
| first_indexed | 2024-03-08T13:17:06Z |
| format | Article |
| id | doaj.art-33f8e71d598843998b66aeb927e96ed7 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-03-08T13:17:06Z |
| publishDate | 2024-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-33f8e71d598843998b66aeb927e96ed72024-01-18T05:49:10ZengPublic Library of Science (PLoS)PLoS ONE1932-62032024-01-01191e028426710.1371/journal.pone.0284267Two risk factors for hypozincemia in diabetic β-thalassemia patients: Hepatitis C and deferasirox.Hadi Darvishi-KhezriHossein KaramiMohammad NaderisorkiMobin GhazaieanMehrnoush KosaryanAmir Mosanejad-GalchaliAily AliasgharianHasan Karami<h4>Background and aim</h4>Hypozincemia is a prevalent adverse consequence in diabetes mellitus (DM) and β-Thalassemia patients. We aimed to evaluate the level of serum zinc in β-thalassemia patients with DM and a risk assessment for hypozincemia.<h4>Methods</h4>The study population included transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT) with overt DM (fasting plasma glucose (FPG) ≥126 mg/dL, and/or 2-h plasma glucose≥200 mg/dL). Serum zinc concentration was measured by the colorimetric method, and the values below 70 μg/dL were defined as hypozincemia. Myocardial and liver T2*-weighted magnetic resonance imaging (MRI T2*, millisecond [ms]) were valued by a free contrast MRI. The demographic, clinical, paraclinical, and laboratory data were also recorded. The data belonged to the period from December 2018 until December 2020.<h4>Results</h4>Of 64 diabetic β-thalassemia patients, 41 cases had zinc data in their medical files (aged 38 ± 9 years, 48.8% female). 78.05% of patients (n = 32) were TDT, and 21.95% were NTDT (n = 9). The mean ± standard deviation of zinc level was 110.2 ± 127.6 μg/dL. The prevalence of hypozincemia was 9.76%, 95% confidence interval [CI] 0.27 to 19.24 (four cases). After controlling age, the odds of hypozincemia for using deferasirox (DFX) was 8.77, 95% CI 0.60 to 127.1. In β-thalassemia patients, the age-adjusted risk of hypozincemia was calculated at 15.85, 95% CI 0.47 to 529.3 for hepatitis C. The adjusted risk of hypozincemia based on age for antacid use was 6.34, 95% CI 0.39 to 102.7.<h4>Conclusion</h4>In light of this study, as well as hepatitis C, using DFX and antacids is associated with a high risk of hypozincemia amid diabetic β-thalassemia cases. However, upward bias should be taken into consideration.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0284267&type=printable |
| spellingShingle | Hadi Darvishi-Khezri Hossein Karami Mohammad Naderisorki Mobin Ghazaiean Mehrnoush Kosaryan Amir Mosanejad-Galchali Aily Aliasgharian Hasan Karami Two risk factors for hypozincemia in diabetic β-thalassemia patients: Hepatitis C and deferasirox. PLoS ONE |
| title | Two risk factors for hypozincemia in diabetic β-thalassemia patients: Hepatitis C and deferasirox. |
| title_full | Two risk factors for hypozincemia in diabetic β-thalassemia patients: Hepatitis C and deferasirox. |
| title_fullStr | Two risk factors for hypozincemia in diabetic β-thalassemia patients: Hepatitis C and deferasirox. |
| title_full_unstemmed | Two risk factors for hypozincemia in diabetic β-thalassemia patients: Hepatitis C and deferasirox. |
| title_short | Two risk factors for hypozincemia in diabetic β-thalassemia patients: Hepatitis C and deferasirox. |
| title_sort | two risk factors for hypozincemia in diabetic β thalassemia patients hepatitis c and deferasirox |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0284267&type=printable |
| work_keys_str_mv | AT hadidarvishikhezri tworiskfactorsforhypozincemiaindiabeticbthalassemiapatientshepatitiscanddeferasirox AT hosseinkarami tworiskfactorsforhypozincemiaindiabeticbthalassemiapatientshepatitiscanddeferasirox AT mohammadnaderisorki tworiskfactorsforhypozincemiaindiabeticbthalassemiapatientshepatitiscanddeferasirox AT mobinghazaiean tworiskfactorsforhypozincemiaindiabeticbthalassemiapatientshepatitiscanddeferasirox AT mehrnoushkosaryan tworiskfactorsforhypozincemiaindiabeticbthalassemiapatientshepatitiscanddeferasirox AT amirmosanejadgalchali tworiskfactorsforhypozincemiaindiabeticbthalassemiapatientshepatitiscanddeferasirox AT ailyaliasgharian tworiskfactorsforhypozincemiaindiabeticbthalassemiapatientshepatitiscanddeferasirox AT hasankarami tworiskfactorsforhypozincemiaindiabeticbthalassemiapatientshepatitiscanddeferasirox |